Literature DB >> 19903424

Natural history and complications of IBD.

Morten H Vatn1.   

Abstract

Inflammatory bowel diseases (IBD), mainly ulcerative colitis and Crohn's disease, are chronic, heterogenic, lifelong illnesses with young age of onset and a great potential for disability. The natural history of these diseases is influenced by multiple factors of environmental and genetic origin. Multidisciplinary research has increased our knowledge of the mechanisms involved during the development and outcome of the diseases, including disease complications. Immunomodulatory treatment has demonstrated greatly improved efficacy in moderate to severe disease activity. The long-term effect on the natural course of disease and sustained reduced burden on society over many years require study. This article summarizes recent knowledge on factors influencing the natural history of IBD, including the impact of treatment. Increased understanding of disease mechanisms is needed as a basis for new treatment strategies in the future.

Entities:  

Mesh:

Year:  2009        PMID: 19903424     DOI: 10.1007/s11894-009-0073-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  62 in total

1.  On the generality of the latitudinal diversity gradient.

Authors:  Helmut Hillebrand
Journal:  Am Nat       Date:  2004-01-15       Impact factor: 3.926

2.  Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years.

Authors:  Ole Høie; Geir Aamodt; Severine Vermeire; Tomm Bernklev; Selwyn Odes; Frank L Wolters; Lene Riis; Patrizia Politi; Epameinondas V Tsianos; Mercedes Butrón; Reinhold W Stockbrügger; Pia Munkholm; Morten Vatn; Bjørn Moum
Journal:  J Crohns Colitis       Date:  2007-11-26       Impact factor: 9.071

3.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 4.  Indeterminate colitis: a review of the concept--what's in a name?

Authors:  Karel Geboes; Jean-Frédéric Colombel; Adrian Greenstein; Derek P Jewell; William J Sandborn; Morten H Vatn; Bryan Warren; Robert H Riddell
Journal:  Inflamm Bowel Dis       Date:  2008-06       Impact factor: 5.325

5.  Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).

Authors:  Magne Henriksen; Jørgen Jahnsen; Idar Lygren; Jostein Sauar; Tom Schulz; Njål Stray; Morten H Vatn; Bjørn Moum
Journal:  Scand J Gastroenterol       Date:  2006-09       Impact factor: 2.423

6.  Clinical patterns of familial inflammatory bowel disease.

Authors:  J Satsangi; C Grootscholten; H Holt; D P Jewell
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 8.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 9.  Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.

Authors:  Sara Renna; Calogero Cammà; Irene Modesto; Giuseppe Cabibbo; Daniela Scimeca; Giuseppe Civitavecchia; Filippo Mocciaro; Ambrogio Orlando; Marco Enea; Mario Cottone
Journal:  Gastroenterology       Date:  2008-08-03       Impact factor: 22.682

10.  Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.

Authors:  Folashade Adebisi Jose; Elizabeth A Garnett; Eric Vittinghoff; George D Ferry; Harland S Winter; Robert N Baldassano; Barbara S Kirschner; Stanley A Cohen; Benjamin D Gold; Oren Abramson; Melvin B Heyman
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

View more
  28 in total

1.  Effects of appendectomy and oral tolerance on dextran sulfate sodium colitis.

Authors:  Min Yue; Zhe Shen; Chao-Hui Yu; Hua Ye; Yue-Fang Ye; You-Ming Li
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

3.  Advances in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

4.  IBD. Fishing for missing heritability in IBD.

Authors:  Michael Pack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-05       Impact factor: 46.802

5.  Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Authors:  Emanuel Burri; Christoph Beglinger; Stefanie von Felten; Frank Serge Lehmann
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

6.  BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis.

Authors:  Han-Xian Zhang; Bin Zhu; Xiao-Xia Fu; Jin-Cheng Zeng; Jun-Ai Zhang; Wan-Dang Wang; Bin Kong; Wen-Yu Xiang; Jixin Zhong; Cong-Yi Wang; Xue-Bao Zheng; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 7.  Crucial steps in the natural history of inflammatory bowel disease.

Authors:  Giovanni Latella; Claudio Papi
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

8.  Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease.

Authors:  Suhyeon Yoo; Yoon Suk Jung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Il Park
Journal:  Gut Liver       Date:  2013-11-05       Impact factor: 4.519

Review 9.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 10.  Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.

Authors:  Tue Bennike; Svend Birkelund; Allan Stensballe; Vibeke Andersen
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.